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g-Secretase is composed of four proteins that are
obligatory for protease activity: presenilin, nicastrin,
Aph1, and Pen-2. Despite the progress toward un-
derstanding the function of these individual subunits,
there is no information available pertaining to the
modulation of g-secretase in response to environ-
mental changes in cells. Here, we show that hypoxia
upregulates g-secretase activity through a direct
interaction with Hif-1a, revealing an unconventional
function for Hif-1a as an enzyme subunit, which is
distinct from its canonical role as a transcription fac-
tor. Moreover, hypoxia-induced cell invasion and
metastasis are alleviated by either g-secretase inhib-
itors or a dominant-negative Notch coactivator, indi-
cating that g-secretase/Notch signaling plays an
essential role in controlling these cellular processes.
The present study reveals a mechanism in which
g-secretase can achieve temporal control through
conditional interactions with regulatory proteins,
such as Hif-1a, under select physiological and path-
ological conditions.
INTRODUCTION
g-Secretase, an intramembranous aspartyl protease composed
of presenilin (PS), nicastrin (Nct), Aph1, and Pen-2, cleaves mul-
tiple type I membrane proteins, including the amyloid precursor
protein (APP) andNotch receptor proteins. Mutations of g-secre-
tase subunits have been associated with Alzheimer’s disease
(Levy-Lahad et al., 1995; Sherrington et al., 1995), acne inversa
(Wang et al., 2010), and acute myeloid leukemia (Klinakis et al.,
2011). Although cellular reconstitution studies suggest that all
four integral membrane proteins are required for g-secretase ac-
tivity (Edbauer et al., 2003), multiple reports indicate that only a
fraction of the steady-state complexes existing in mammalian
cells are catalytically active and that g-secretase activity is notCelalways correlated with the levels of presenilin (Beher et al.,
2003; Gu et al., 2004; Lai et al., 2003; Placanica et al., 2009),
the catalytic subunit of g-secretase (Ahn et al., 2010). Thus, the
function of the inactive complexes remains poorly understood.
Several g-secretase-interacting proteins, including CD147
(Zhou et al., 2005), p23/TMP21 (Chen et al., 2006), and g-secre-
tase-activating protein (GSAP) (He et al., 2010), have been
described tomodulate g-secretase activity and specificity. How-
ever, it is unknown whether g-secretase can be conditionally
modulated as an adaptive response to environmental stressors.
Notch and hypoxia-inducible factor-1a (Hif-1a) signaling path-
ways control many essential biological processes, from stem cell
development to organogenesis, and the crosstalk between both
pathways has been investigated in several biological systems
(Gustafsson et al., 2005; Mukherjee et al., 2011; Wang et al.,
2011). Hif-1a, a master regulator of cellular response to hypoxia,
regulates the expression of numerous Hif-responsive genes,
including vascular endothelial growth factor (VEGF), which is
essential for angiogenesis, and glucose transporter 1 (Glut-1),
which is essential for increased glucose utilization (Denko,
2008). Multiple studies also have shown that Hif-1a can poten-
tiate Notch signaling. For example, Hif-1a was shown to bind
and stabilize the Notch intracellular domain (NICD) (Gustafsson
et al., 2005), which is generated by g-secretase cleavage and
translocates to the nucleus to activate Notch target genes.
Furthermore, the crosstalk between Notch and Hif-1a is required
tomaintain an undifferentiated cell state under hypoxia (Gustafs-
son et al., 2005). Alternatively, it has been shown that Hif-1a can
bind to the N boxes in the promoter region of Hes1, a Notch
target gene, to alleviate the negative feedback of Notch signaling
in cancer stem cells (Wang et al., 2011). In addition, the Aph1a
gene promoter contains a Hif-1a response element (HRE) bind-
ing site and chemical hypoxia has been shown to lead to the up-
regulation of g-secretase activity through an increase in Aph1a
gene expression (Wang et al., 2006). Sima, aDrosophila ortholog
of Hif-1a, has also been reported to activate Notch signaling
in a ligand-independent manner to promote the survival of
Drosophila blood cells (Mukherjee et al., 2011). Collectively,
these studies indicate that multiple mechanisms can be involved
in the regulation of Notch signaling by Hif-1a.l Reports 8, 1077–1092, August 21, 2014 ª2014 The Authors 1077
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Figure 1. Hypoxia Potentiates g-Secretase Activity
(A) Schematic of exocell g-secretase activity assay. Breast cancer cells are cultured in normoxia or hypoxia for 24 hr. The level of enzyme activity was determined
by the amount of cleaved N1-Sb1 substrate, as detected using NICD-specific SM320 antibody and AlphaLISA donor and acceptor beads.
(B) Hypoxia increases g-secretase activity in breast cancer cells. g-Secretase activity is expressed as arbitrary units (A.U.).
(C) Western blot analysis of NICD1 generated from g-secretase cleavage of N1-DE-myc in breast cancer cells cultured in normoxia or hypoxia. The generation of
NICD1 via g-secretase cleavage was detected by SM320 antibody. Anti-Myc detects expression of uncleaved N1-DE-myc. Compound E, a GSI, abrogates the
production of NICD1.
(legend continued on next page)
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Hypoxia is a common phenomenon shared among many
solid tumors and is correlated with poor prognosis and tumor
invasiveness (Denko, 2008). The crosstalk between Hif-1a and
Notch leads to enhanced activation of Notch signaling, which
drives epithelial-to-mesenchymal transition events, such as
cell motility and invasiveness (Sahlgren et al., 2008). Therefore,
investigation of the interplay between Hif-1a and Notch/g-sec-
retase is critical to understand their role in pathophysiology of
cancer and other human disorders. In the present study, we
show that hypoxia leads to augmentation of g-secretase activ-
ity by direct binding of Hif-1a to the g-secretase complex rather
than by Hif-1a’s conventional transcriptional activity. Moreover,
an increase in g-secretase activity and Notch signaling is crit-
ical for hypoxia-induced cell migration, invasion, and metas-
tasis of breast cancer. This work reveals an unconventional
role for Hif-1a as a regulatory subunit of the g-secretase com-
plex under low-oxygen environments and a mechanism for
temporally controlling g-secretase activity in response to oxy-
gen deprivation.
RESULTS
Hypoxia Increases g-Secretase Activity
Increasing evidence suggests that the upregulation of Notch
signaling promotes breast cancer development (Al-Hussaini
et al., 2011; Stylianou et al., 2006). Therefore, we set out to
examine if hypoxia potentiates g-secretase activity and the pro-
duction of Notch1 intracellular domain (NICD1) in breast cancer
cells. To directly measure the effect of hypoxia on g-secretase,
we applied an exocell assay (Shelton et al., 2009a) using a re-
combinant Notch substrate, N1-Sb1 (Chau et al., 2012), which
allows for the immediate and real-time analysis of g-secretase
activity without the requirement of cell transfections or mem-
brane preparation (Figure 1A). Three human breast cancer cell
lines (MCF-7, MDA-MB-231, and MDA-MB-468) and one mouse
mammary cancer cell line (4T1) were seeded in a 96-well format
andwere cultured under normoxic or hypoxic conditions (1%O2)
for 24 hr. The recombinant substrate, N1-Sb1, was then added to
the cells in the presence of the detergent, CHAPSO (3-[(3-chola-
midopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate),
and incubated for an additional 2.5 hr to allow for g-secretase
cleavage. Finally, the N1-Sb1-derived product was detected
with an AlphaLISA assay (Chau et al., 2012) (Figure 1A). The spe-
cific activity of g-secretase was determined by normalizing to
protein concentration. Hypoxia led to a significant increase in
g-secretase activity in all four cell lines examined (Figure 1B).
Compared with normoxia, hypoxia increased g-secretase activ-
ity by 1.6-, 2.9-, 2.9-, and 3.0-fold for MCF-7, MDA-MB 231,
MDA-MB 468, and 4T1 cells, respectively (Figure 1B). We next
examined the effect of hypoxia on g-secretase-mediated
NICD1 production in a cellular setting by transfecting a myc-(D) Quantitative measure of NICD1 production from g-secretase cleavage using A
to measurements in (B), NICD was detected with AlphaLISA technology with a pai
signal in arbitrary units (A.U.).
(E) Reciprocal immunoprecipitation of HA-Hif-1a-DODD and FLAG-NICD1 with H
noblotting with FLAG antibody detects only FLAG-NICD1 and not HA-Hif-1a-DOD
not FLAG-NICD1. All data are presented as mean ± SD (nR 3) and two-tailed u
Celtagged version of N1-DE (N1-DE-myc), a truncated form of
Notch1 that is cleaved by g-secretase in a ligand-independent
manner (Schroeter et al., 1998). MCF-7 and MDA-MB468
were transfected with N1-DE-myc for 24 hr and then cultured un-
der normoxia or hypoxia for another 24 hr. The steady-state
levels of NICD1 were then assayed by western blot analysis.
We observed a clear increase in NICD1 generation in hypoxia-
treated cells compared with cells cultured in normoxic con-
ditions (Figure 1C). The specificity of protease activity was
confirmed by the use of g-secretase inhibitor, Compound E.
Further quantitative analysis with AlphaLISA assay to detect
NICD1 showed that hypoxia led to an increase in the accumula-
tion of NICD1 by 170% and 150% in MCF-7 and MDA-MB-468,
respectively (Figure 1D). We then determined whether Hif-1a
binds to NICD1 in breast cancer cells under hypoxia, as was
previously reported (Gustafsson et al., 2005). FLAG-NICD1 and
hemagglutinin (HA)-Hif-1a-DODD (a variant of Hif-1a that lacks
the oxygen-sensing domain [ODD] and thus is stable in nor-
moxia; Tanimoto et al., 2000) were coexpressed in MCF-7 cells.
However, reciprocal coimmunoprecipitation studies with anti-
HA and anti-FLAG failed to reveal any interaction between
FLAG-NICD1 and HA-Hif-1a-DODD, while the same antibodies
were able to immunoprecipitate their respective targets, Hif-
1a-DODD and NICD1, respectively (Figure 1E). Taken together,
these findings strongly indicate that increase in NICD1 produc-
tion under hypoxia is mediated through the upregulation of
g-secretase activity rather than the direct interaction of Hif-1a
and NICD1 (Gustafsson et al., 2005).
Hypoxia Does Not Increase the Level of g-Secretase
Subunits
To elucidate the mechanism of the upregulation of g-secretase
activity by hypoxia, we performed western blot analyses to
examine the steady-state protein levels of each g-secretase
subunit under normoxic and hypoxic conditions. The accumula-
tion of Hif-1a confirmed that these cells were cultured in hypoxic
conditions, while Hif-1b, a Hif-1a binding partner, was present
under both conditions (Figure 2A). More importantly, the levels
of PS1-NTF, PS1-CTF, Nct, Aph1a, and Pen2 were unchanged
in all cell lines cultured in normoxic or hypoxic conditions (Fig-
ure 2A). Notably, hypoxia did not increase the level of Aph1a (Fig-
ure 2A; Figure S1A), a finding inconsistent with an earlier report
(Wang et al., 2006), which showed that chemical hypoxia
increased the expression of Aph1a. Whether this discrepancy
is the result of different treatment paradigms (1% O2 versus
NiCl2) is not known. Nevertheless, our findings clearly reveal
that hypoxia-induced elevation in g-secretase activity is not
the result of an increase in the overall steady-state levels of
each subunit.
It is known that only a small fraction of g-secretase com-
plexes are catalytically active (Beher et al., 2003; Crump et al.,lphaLISA detection shows increase in NICD production under hypoxia. Similar
r of antibodies (biotinylated anti-Myc and SM320). Data are expressed as NICD
A and FLAG antibodies in cells coexpressing Hif-1a and NICD1. Left: immu-
D. Right: immunoblotting with HA antibody detected only HA-Hif-1a-DODD and
npaired t test was used for statistical analysis (*p < 0.05, **p < 0.01).
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Figure 2. Hypoxia Increases the Formation of Active g-Secretase
Complex but Not the Amount of Subunits
(A) Western blot analysis of total g-secretase subunits PS1-NTF, PS1-CTF,
Nct, Aph1a, and Pen2 under hypoxia of breast cancer cell lines MCF-7, MDA-
MB 231, MDA-MB 468, and 4T1. Hif-1a is only expressed under hypoxia, and
Hif-1b is expressed in both conditions.
(B) Structure of photoprobe JC-8.
(C) Western blot analysis of the level of PS1-NTF in active g-secretase
formation using PS1-NTF antibody from JC-8 photolysis of MCF-7 and MDA-
MB 468 cells in normoxia or hypoxia. Specificity of JC-8 labeling of the active
g-secretase is represented by addition of L-685,458 as a control to block the
binding of JC-8. Quantitation of labeling intensity by JC-8 was performed in all
cell lines (right).2013; Gu et al., 2004; Lai et al., 2003; Placanica et al., 2009).
Indeed, g-secretase activity is better correlated with the levels
of PS that can be crosslinked with an activity-based photoprobe1080 Cell Reports 8, 1077–1092, August 21, 2014 ª2014 The Authorrather than the total levels of PS (Lai et al., 2003; Placanica
et al., 2009). Therefore, we assessed the levels of active g-sec-
retase using an activity-based photoprobe, JC-8 (Chun et al.,
2004) (Figure 2B), a transition-state inhibitor that only interacts
with the active enzyme. Although the levels of PS1-NTF are
identical in lysates of cells cultured under both conditions (see
Figure 2A), we found a significantly higher level of JC-8 labeled
PS1-NTF in the hypoxia-treated cells than in the normoxic cells
in all four cell lines (Figure 2C). The labeling is highly specific, as
addition of an excess of the parental L685-458 compound in-
hibited JC-8 photoinsertion into PS1-NTF (Figure 2C, left).
These results establish that hypoxia does not potentiate g-sec-
retase activity by increasing the amount of individual subunits of
g-secretase.
Hif-1a Is Required for Upregulation of
g-Secretase Activity
To explore the mechanism(s) by which hypoxia upregulates
g-secretase activity, we investigated Hif-1a, a transcription fac-
tor that is essential for orchestrating cellular responses in low
O2 concentrations. We first asked whether small hairpin RNA
(shRNA)-mediated suppression of Hif-1a expression affects
the observed hypoxia-mediated enhancement of g-secretase
activity. Three MCF-7 cell lines (lines #90, #91, and #10) that
stably express specific shRNA for Hif-1a knockdown were
generated, in addition to a scramble control shRNA stable
cell line. Under hypoxic conditions, Hif-1a protein was virtually
undetectable in the 90, 91, and 10 cell lines, but continued to
be expressed in the control line (Figure 3A). Importantly, deple-
tion of Hif-1a in the MCF-7 knockdown cell lines eliminated
hypoxia-induced augmentation of g-secretase activity (Fig-
ure 3B), while the control cells retained the ability to potentiate
g-secretase activity upon exposure to hypoxic conditions.
These findings indicate that Hif-1a is necessary to upregulate
g-secretase activity under hypoxic conditions. In support of
this, expression of HA-Hif-1a-DODD in MCF-7 cells resulted
in a 1.5-fold increase in g-secretase activity, compared with
control vector-transfected cells under normoxic conditions
(Figure 3C). Furthermore, the expression of HA-Hif-1a-DODD
did not alter the overall level of PS1 (Figure 3D). However, the
amount of JC-8-labeled PS1-NTF species is increased
(Figure 3E).
We next downregulated the expression of prolyl-hydroxylase
2 (PHD2), a key enzyme that promotes the degradation of
Hif-1a under normoxia (Aprelikova et al., 2004; D’Angelo et al.,
2003), and examined its effect on g-secretase. Knockdown of
PHD2 by shRNA14 and 17 was confirmed by western blotting
for PHD2 protein in MCF-7 cells (Figure S1B, top). The knock-
down of PHD2 led to an accumulation of Hif-1a levels (Fig-
ure S1B, middle) and an increase (2- to 4-fold) in g-secretase
activity in comparison to scramble control (Figure S1C). Addi-
tionally, it appears that the degree of g-secretase activity in-
crease could be correlated with the degree of PHD2 knockdown
and Hif-1a expression.
Taken together, both the knockdown and enhancement of
cellular Hif-1a levels demonstrate that Hif-1a is necessary and
sufficient for the upregulation of g-secretase activity in hypoxic
conditions.s
Hif-1a-Mediated g-Secretase Potentiation Is
Independent of Its Transcriptional Activity
Findings showing that g-secretase activity is elevated under
hypoxic conditions without changing the individual subunit levels
suggest that Hif-1a may regulate g-secretase through a unique
mechanism. We first asked whether Hif-1a plays a nontranscrip-
tional role in modulating g-secretase activity. Echinomycin has
been reported to be a Hif-1a inhibitor that specifically interca-
lates into the HRE to prevent the binding of the Hif-1a/Hif-1b
complex, which is necessary to activate transcription (Wang
et al., 2011) (Figure S1D, top). After the echinomycin treatment
of 4T1 cells at 0.1 and 0.3 nM under both normoxic and hypoxic
conditions, we examined for the transcription of VEGF-A, a
Hif-1a target gene, and found that the drug treatment reduced
Hif-1a transcriptional activity in a concentration-dependent
manner (Figure S1D, bottom). The treatment, however, did not
exert an effect on the protein expression of Hif-1a or PS1-NTF
(Figure S1E). Moreover, in hypoxic breast cancer cells, chemical
inhibition of Hif-1a by echinomycin did not abrogate the stimula-
tion in g-secretase activity (Figure S1F). These studies suggest
that hypoxia augments g-secretase activity through an unknown
mechanism that is independent of the transcriptional activity of
Hif-1a.
The Hif-1a and Hif-1b (ARNT) heterodimer is necessary for the
transactivation and DNA binding properties of Hif-1a (Chilov
et al., 1999). In order to further examine potential transcriptional
roles of Hif-1a on g-secretase activity, we suppressed Hif-1b
levels using shRNA knockdown and measured g-secretase
activity in hypoxic and normoxic conditions. Hif-1b is virtually un-
detectable in two MCF-7 stable cell lines (#598 and # 599) that
express shRNA under both conditions (Figure 3F). Notably, the
stimulation of activity was still observed under hypoxia in the
absence of Hif-1b expression (Figure 3G), providing another
line of evidence that the transcriptional activity of Hif-1a is not
required for hypoxia-induced g-secretase potentiation.
To further test that Hif-1a can indeed nontranscriptionally
regulate g-secretase activity, we utilized a Hif-1a mutant basic
helix-loop-helix (bHLH) (Hu et al., 2006). This mutant has four
conserved basic residues within the Hif-1a DNA binding domain
mutated to alanines so the bHLH region can no longer bind the
HRE and activate HIF inducible genes (Hu et al., 2006). We ex-
pressed the Hif-1a mutant bHLH tagged with FLAG epitope in
MCF-7 cells and showed that while the level of PS1-NTF was
not altered (Figure 3H, left), expression of this mutant was still
able to increase g-secretase activity (Figure 3H, right). This indi-
cates that a transcription-deficient Hif-1a mutant is still capable
of stimulating g-secretase activity.
Lastly, to determine if full-length Hif-1a is required for g-secre-
tase stimulation, we utilized three FLAG-tagged Hif constructs
that include a full-length Hif-1a with triple mutations (Hif-1a-FL-
TM, which contains P420A, P557A, and N813A mutations), a
truncated Hif-1a N-terminal fragment (Hif-1a-NTF, amino acids
1–364), and Hif-1a C-terminal fragment (Hif-1a CTF, D10–370).
Hif-1a-FL-TM is a stable construct under normoxia, Hif-1a-NTF
lacks both the N-TAD and C-TAD domains that are important
for transcriptional activity, and Hif-1a-CTF does not contain
bHLH and Per-Arnt-Sim (PAS) domains (Hu et al., 2007). All three
constructs were expressed as detected by anti-FLAG (Figure 3I,Celtop) and had no effect on the level of PS1 (Figure 3I, low). The
expression of Hif-1a-FL-TMorHif-1a-NTF alone inMCF-7 breast
cancer cells was able to potentiate g-secretase activity under
normoxia. Hif-1a-CTF expression, however, was unable to stim-
ulate g-secretase activity (Figure 3I, right). These observations
indicate that the transcriptional activity of Hif-1a is not required
for the augmentation of g-secretase proteolytic activity and
that the point of interaction between these proteins may reside
within the N-terminal domain of Hif-1a. Collectively, our data
demonstrate that Hif-1a regulates g-secretase activity indepen-
dently from its transcriptional function.
Hif-1a Directly Interacts with the g-Secretase Complex
Next, we tested the hypothesis that Hif-1amodulates the activity
of g-secretase through a direct association with the enzyme
complex. The g-secretase complex was isolated using an activ-
ity-based probe, Compound 3 (Figure 4A) (Placanica et al.,
2009), in order to assess if Hif-1a associates with the complex.
Both Compound 3 and a nonbiotinylated version of this com-
pound exhibit the same inhibitory profiles (Figure S2A), suggest-
ing that both are equally capable of binding to the complex and
capturing g-secretase and associated proteins. The 4T1 cells
were cultured under hypoxic conditions, lysed, and solubilized
with CHAPSO. Solubilized g-secretase complexes from cell ly-
sates and components of the isolated active complex by Com-
pound 3 were assessed by western blot analysis. The obligatory
g-secretase components (PS1-NTF, PS1-CTF, Aph1a, Nct, and
Pen2) were captured under both normoxic and hypoxic condi-
tions (Figure 4B). Compound 3 also captured Hif-1a from
CHAPSO-solubilized fraction in hypoxia-treated cells and not
in normoxia (Figure 4C). On the other hand, Hif-1b, which exists
in both normoxia and hypoxia samples, was not captured by the
activity-based probe, indicating that Hif-1a itself was selectively
engaged with the active g-secretase complex and not with the
Hif-1a/Hif-1b transcriptional complex. These activity-based
capture studies fully support the earlier Hif-1a and Hif-1b knock-
down experiments (see Figure 3 and 4). Furthermore, we found
that, in hypoxia, Compound 3 captured elevated levels of all
four subunits of g-secretase specifically. This suggests that
Hif-1a binding to the complex increases the overall level of active
g-secretase complexes (Figure 4B). The isolation of g-secretase
subunits and Hif-1a by Compound 3 was specific, as an excess
concentration of the parent compound, L-685,458, blocked the
capture of both the g-secretase complex and Hif-1a. Further an-
alyses of PS1 in the active complex showed that the level of
captured PS1-NTF and PS1-CTF in hypoxia is approximately
3- to 5-fold higher than in normoxia (Figure S2B, western blot
at the top, quantitation of the blots at the bottom). We also
captured Hif-1a together with the g-secretase complex from
the CHAPSO-solubilized hypoxic lysates from MDA-MB 231
and MDA-MB 468 cells as well (Figure S2C).
In normoxic conditions, but not in control cells, Compound 3
was able to specifically capture FLAG-tagged Hif-1a-FL-TM in
MCF-7 cells that expressed this protein (Figure S2D). Addition-
ally, overexpression of Hif-1a-FL-TM increased the level of
PS1-NTF capture as compared to control cells that did not ex-
press the construct, again to further support that the expression
of Hif-1a enhances the formation of active g-secretase complex.l Reports 8, 1077–1092, August 21, 2014 ª2014 The Authors 1081
Figure 3. Hif-1a Is Necessary for Upregulation of g-Secretase Activity but Independent of Its Transcriptional Activity
(A) Validation of Hif-1a knockdown bywestern blot analysis. shRNA targeting Hif-1awas retrovirally introduced inMCF-7 cells and grown under hypoxia. Controls
are nontargeting scramble sequence shRNA.
(B) Effect of Hif-1a knockdown on the activity of g-secretase in MCF-7 cells in normoxia and hypoxia. Data are expressed as fold g-secretase activity (normoxia/
hypoxia).
(C) g-Secretase activity assay of MCF-7 expressing HA-Hif-1a-DODD construct compared to vector control. Data are represented as arbitrary units (A.U.).
(D) Expression level of HA-Hif-1a-DODD and PS1-NTF compared to vector-only control in MCF-7 cells in normoxia.
(legend continued on next page)
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To further determine the interaction between the g-secretase
complex and Hif-1a, we utilized immunoprecipitation to assess
their direct association. Immunoprecipitation of CHAPSO-solu-
bilized MCF-7 cells cultured under hypoxia using an anti-PS1
was able to pull down both PS1-NTF (Figure 4D, bottoml) and
Hif-1a (Figure 4D, top). Equivalent amounts of control nonspe-
cific rabbit immunoglobulin G did not precipitate PS1 or HIF-1a
(Figure 4D). These findings strongly support our hypothesis
that Hif-1a directly interacts with the g-secretase complex.
In addition, we fractionated CHAPSO-solubilized MCF-7
lysate using a 10%–40% glycerol density gradient to analyze
the distribution of g-secretase subunits and Hif-1a (Figure S2E).
Western blot analysis of the g-secretase complex components
showed similar distribution of overall protein subunit in both nor-
moxic and hypoxic samples (Figure S2E). Hif-1a was mainly de-
tected in fractions #3–8 and #11 of the hypoxic lysate. To further
determine the level of association of Hif-1awith the active g-sec-
retase complex, each fraction was subjected to Compound
3 capture. Using anti-Hif-1a and anti-PS1 antibodies, western
blot analysis identified that fraction #11 contains the most highly
active fraction, as indicated by the presence of PS-NTF labeled
under both conditions (Figure S2F). These data are consistent
with a previous study, which reported that a g-secretase com-
plex with amolecular mass of greater than 660 kDa is competent
for protease activity (Gu et al., 2004). Our study shows that
although higher levels of Hif-1a were present in fractions #3-8
as compared to #11 in the hypoxic sample, only Hif-1a from frac-
tion #11 was captured. This clearly demonstrates that the cap-
ture of Hif-1a with Compound 3 is dependent on the presence
of active g-secretase complex and that Compound 3 does not
bind to Hif-1a alone. These findings indicate that Hif-1a acts as
a regulatory subunit of g-secretase and enhances the level of
active complex by recruiting and activating otherwise inactive
complexes, leading to an increase in g-secretase activity.
To directly examine the role of Hif-1a in stimulating g-secre-
tase activity, we developed an in vitro system using recombinant
Hif-1a. We expressed full-length Hif-1a fused to the maltose-
binding protein (MBP) at the N terminus and MBP itself in
E. coli. Both MBP-Hif-1a and MBP were purified to homogeneity
with Amylose affinity chromatography (Figure 4E). MBP-Hif-1a
or MBP was cosolubilized with MCF-7 cell lysates for 1 hr at
4C in the presence of 1% CHAPSO detergent. The solubilized
fraction was then diluted to 0.25% CHAPSO and assayed for
g-secretase activity using the in vitro activity assay or the activ-
ity-based photoprobe, JC-8 (Figure 4F). Addition of MBP-Hif-1a
to MCF-7 cell lysates significantly enhanced g-secretase activity
by 2-fold compared to the control. (Figure 5F, bottom left).(E) Active-site photolysis of HA-Hif-1a-DODD overexpressing MCF-7 cells in no
using western analysis.
(F) Validation of Hif-1b knockdown in MCF-7 cells using retrovirally transduced s
(G) Effect of Hif-1b knockdown on the activity of g-secretase in MCF-7 cells. Hif-1b
normoxia. Data are expressed as fold g-secretase activity (normoxia/hypoxia).
(H) Expression of FLAG-taggedmutant bHLH is verified by anti-FLAG (left ) and led
(A.U.).
(I) Expression of Hif-1a-TM, Hif-1a-NTF andHif-1a-CTFwere confirmed by tagged
Hif-1a-TM and Hif-1a-NTF, but not Hif-1a-CTF, potentiates the g-secretase activi
evaluated by two-tailed unpaired t test, where *p < 0.05, **p < 0.01, and ***p < 0
CelSimilarly, the activity-based labeling detected higher levels of
PS1-NTF in MCF-7 cell lysates reconstituted with MBP-Hif-1a
than with lysates containing MBP (Figure 4F, bottom right).
Thus, we have demonstrated that recombinant Hif-1a, alone,
was sufficient to potentiate g-secretase activity and activity-
based labeling of PS1-NTF. These biochemical reconstitution
studies, alongwith our demonstration of the cocapture of endog-
enous Hif-1a with the native g-secretase complexes in hypoxic
cultured cells and coimmunoprecipitation of PS1 andHif-1a (Fig-
ures 4B–4D), establish that Hif-1a operates as a regulatory
g-secretase subunit under hypoxic conditions. Mechanistically,
photoaffinity labeling and the capture studies using the activ-
ity-based probes suggest that Hif-1a converts a population of
inactive complexes to active complexes and thus upregulates
g-secretase activity through a mechanism that is independent
of its canonical transcriptional function (Figure 4G).
g-Secretase Inhibitor Blocks Hypoxia-Induced Cell
Invasion and Metastasis in Cells and In Vivo
Hypoxia drives cancer cells to become more malignant, a
phenotype that is marked by an increase in cellular migration
and invasion (Denko, 2008). To examine the role of hypoxia-
induced g-secretase activity in breast cancer, we determined
the migratory propensity of 4T1 and MDA-MB 231, two invasive
breast cancer cell lines, in the absence and the presence of
GSI-34, a potent g-secretase inhibitor (Figure 5A, top) (Placanica
et al., 2010; Shelton et al., 2009a). GSI-34 has a half maximal
inhibitory concentration (IC50) of 40–70 nM in a cell-based
Notch1 reporter assay under both normoxic and hypoxic condi-
tions (Figure 5A, bottom). Moreover, inhibition of hypoxia-acti-
vated Notch signaling was demonstrated by the suppression
of Hes1 mRNA levels in 4T1 cells using GSI-34 (Figure 5B). We
then determined the effect of g-secretase inhibition on cellular
migration using a wound-healing assay under hypoxia. GSI-34
attenuated wound closure of MDA-MB 231 cells by 21% and
50% at 1 and 10 mM, respectively (Figure 5C). Similarly, GSI-34
also significantly blocked cell migration of 4T1 cells (Figure 5D).
To assess the effect of g-secretase inhibition on cell invasive-
ness, 4T1 cells or MDA-MB 231 cells were seeded in nonserum
media onto Matrigel coated transwell inserts and allowed to
invade overnight under hypoxia through wells with serum con-
taining media. GSI-34 treatment effectively prevented the inva-
sion of 4T1 cells through the Matrigel platform in a concentration
dependent manner; concentrations of 0.1, 1, and 10 mM led to a
reduction in cell invasion by 62%, 78%, and 89%, respectively
(Figure 5E). Similarly, the compound reduced the invasiveness
of MDA-MB 231 cells under hypoxia. GSI-34 at 10 mM wasrmoxia compared to vector-only control as detected using PS1-NTF antibody
hRNA in normoxia and hypoxia.
knockdown cells in hypoxia exhibited greater g-secretase activity than cells in
to increase in g-secretase activity (right). Data are presented as arbitrary units
FLAG antibodies and had no effect on the level of PS1-NTF (left). Expression of
ty (right). All data are presented as mean ± SD (nR 3). Statistical significance is
.001.
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(A) Structure of g-secretase capture probe Compound 3.
(B) Affinity capture of all g-secretase complex components by Compound 3 with normoxic and hypoxic 4T1 cell lysate and analyzed by western blot analysis.
(C) Hif-1a is pulled down with Compound 3 in 4T1 under hypoxia, while Hif-1b is not captured under either condition. Specificity of capture is demonstrated by
L-685,458.
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(E) Recombinant expression and purification of MBP (left) and MBP-Hif-1a fusion protein (right) in E. coli. Purified proteins were visualized on SDS-PAGE by
Coomassie staining.
(legend continued on next page)
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able to reduce MDA-MB 231 cell invasion by 77% (Figure 5F). In
addition, while there appears to be some cellular toxicity at
10 mM, GSI-34 at lower concentrations did not affect cell viability
(Figure S3). These results demonstrate that inhibition of g-secre-
tase significantly blocks hypoxia-induced invasion of MDA-MB
231 and 4T1 cells.
To determine the effect of g-secretase inhibition on tumor
migration and metastasis in vivo, we utilized a luciferase-
expressing breast cancer cell line, 4T1/luc, frequently used to
model stage IV breast cancer (Tao et al., 2008). The 4T1/luc
mouse mammary cancer cell line can be orthotopically injected
into the mammary fatpad. Stable expression of firefly luciferase
and in vivo luminescence imaging allows for longitudinal moni-
toring of tumor growth and metastasis to distant organ sites,
such as the lung, a common first site of metastasis (Tao et al.,
2008). The 4T1/luc cells (1 million) were implanted at the inguinal
mammary fat-pad of female BALB/c mice on day 0. At day 5
postimplantation, animals were imaged for luciferase activity
and all mice with similar tumor loads were randomized and sepa-
rated into three treatment groups (vehicle and 80 and 160 mg/kg
of GSI-34). Animals received treatment with GSI-34 by intraper-
itoneal injection a total of seven times. No toxicities including
weight loss and diarrhea were observed in these mice. From
day 5 onward, primary tumor volume was measured every other
day with calipers. GSI-34 moderately reduced primary tumor
size by 27% and 40% at 80 mg/kg and 160 mg/kg, respectively
(Figure 6A).
To monitor the effect of GSI-34 on the distant metastasis of
4T1/luc cells, mice were injected with D-luciferin and imaged
for luminescence. Progression of metastasis was monitored by
quantitation of bioluminescence signal in the thoracic region of
the animal. We were able detect lung metastases in control
mice on day 18. Animals treated at both doses of GSI-34 ex-
hibited reduction in distant metastasis compared to the control
group, as determined by the quantification of total flux emitted
by the 4T1/luc cells (Figures 6B and 6C) on day 20. Immediately
following whole-animal imaging, the lungs from four random
representative animals of each treatment group were harvested
and imaged ex vivo. Three out of four excised lungs from the
control group were positive for 4T1/luc, while in the 80 mg/kg
GSI-34 treatment group, only one lung was luciferase positive.
We did not detect any luminescence signal in the animals treated
with GSI-34 at 160 mg/kg. Next, we assessed the effect of GSI-
34 treatment on g-secretase activity in primary 4T1/luc tumors
ex vivo. Tumor lysate of the primary tumors were assayed for
g-secretase activity using the N1-Sb1 substrate, as previously
described. GSI-34 treatment demonstrated dose-dependent
inhibition of g-secretase activity in tumor tissue membrane
(Figure 6E). Overall, GSI-34 treatment resulted in reduction of(F) Reconstitution of Hif-1a mediated g-secretase activity in MCF-7 cells with re
Hif-1a or MBP in 1% CHAPSO. Lysates are then used for g-secretase activity a
expressed as % g-secretase activity/control, where MBP-treated cell lysate was
active PS1 as compared to the MBP control in both MCF-7 and 4T1 cell lines (b
nificance is evaluated by two-tailed unpaired t test, where *p < 0.05 and **p < 0.
(G) Model of g-secretase activity activation by Hif-1a. Inactive g-secretase is inca
shown by broken scissors. Hif-1a converts inactive g-secretase to the active en
initiate catalysis.
Cel4T1/luc tumor burden, distant metastases, and g-secretase
activity in tumor lysates.
Lung metastases were examined using histological tech-
niques on day 22. Hematoxylin and eosin (H&E) staining of
formalin-fixed lung samples showed differential degree of can-
cer cell colonization in lungs of control and treated mice. Lungs
from control animals exhibited a higher incidence of metastatic
lesions and larger metastatic foci compared to lungs from
GSI-34-treated animals (Figure 6D). Tumor hypoxia within pri-
mary tumors was examined by immunohistochemical staining
for glucose transporter-1 (Glut-1), a marker shown to correlate
with hypoxia (Airley et al., 2003; Vleugel et al., 2005). Glut-1 stain-
ing was observed in all samples at a similar level, indicating hyp-
oxic regions within the tumors were present in both treated and
untreated samples (Figure 6F).
Downregulation of Notch Signaling by DnMAML1
Reduced Lung Metastasis In Vivo
We next investigated whether the effect of GSI-34 treatment on
breast cancer cell invasion and metastasis was mediated
through the Notch signaling pathway. We thus created a domi-
nant-negative Mastermind-like1 (DnMAML1) version of the
4T1/luc cell line that can effectively block Notch signaling (Nam
et al., 2003). The stable expression of DnMAML1 in 4T1 cell
line showed reduced expression of Hes1 mRNA, indicating
that Notch signaling is significantly impaired (Figure 7A). More-
over, DnMAML1 expression did not affect 4T1 cell proliferation
or g-secretase activity in normoxic or hypoxic conditions (Fig-
ures S4A and S4B). Cell invasion under hypoxia was greatly
enhanced in empty vector-expressing control, whereas
DnMAML1 cells failed to invade through the Matrigel (Figures
S4C and S4D). Notably, the degree of cell invasiveness under
hypoxia for DnMAML1 cells was similar to control cells treated
with GSI-34. In both cases, there was a reduction in cell invasion
by approximately 50% compared with the control, untreated
cells (Figures S4C and S4D). These experiments strongly sug-
gest that g-secretase-mediated Notch signaling is the driver of
cellular invasion processes and does not play a significant role
in the proliferation of breast cancer in hypoxic conditions.
To further understand whether Notch signaling mediates
breast cancer metastases in vivo, we orthotopically implanted
1 million DnMAML-1 4T1/luc cells or control 4T1/luc cells into
the mammary fatpad of BALB/c mice. Primary tumor volume
was measured over the course of the 21-day period and meta-
static spread was monitored by luminescence imaging analysis.
The progression of primary tumor growth in DnMAML1-bearing
mice and control mice were very similar (Figure 7B), supporting
that the downregulation of Notch signaling did not have major
antiproliferative effects. On day 18, luminescence signals fromcombinant MBP-Hif-a or MBP. MCF-7 cells are first cosolubilized with MBP-
ssay or JC-8 photolysis in 0.25% CHAPSO (bottom). Stimulation of activity is
used as a control (bottom left). JC8 photolysis showed increased labeling of
ottom right) All data are presented as mean ± SD (n R 3), and statistical sig-
01.
pable of catalysis and is represented by uncoordinated catalytic Asp residues,
zyme by repositioning the catalytic dyad, as shown by functional scissors to
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Figure 5. g-Secretase Inhibitor Blocks Hypoxia-Promoted Cell Invasion
(A) Structure of GSI-34, a sulfonamide GSI, and IC50 using 8X-CBF-firefly luciferase Notch reporter assay under normoxic and hypoxic conditions.
(B) Quantitative RT-PCR analysis ofHes1 expression in breast cells in hypoxia or normoxia in the presence and absence of GSI-34. Data are expressed as relative
mRNA expression compared to b-actin.
(C) Sensitivity of MDA-MB 231 cell migration to GSI-34 in wound-healing assay. Quantitation by ImageJ analysis of % of area covered by cells is represented in
the right. Data are represented as mean (±SD) and expressed as % of area covered.
(legend continued on next page)
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the thoracic region the animals injected with murine stem cell vi-
rus retroviral expression vector control cells could be detected,
indicating metastatic spread, compared to little or no signal
from the DnMAML1 animals (Figure 7C).
On day 18, we randomly chose half of the mice from each
group to monitor metastatic progression to the lung. Three of
the four mice from the control group had lung metastases, while
no mice (zero out of five) from the DnMAML1 group displayed
lung metastases (Figure 7D, top). By day 21, all control animals
(five out of five) were positive for lung metastases with large met-
astatic lesions and only two of the five DnMAML1 mice had lung
metastasis (Figure 7D, bottom).
We did not include a control mouse for ex vivo imaging on day
18 since it had died just prior to our analysis. However, H&E lung
staining from this mouse did reveal large portions of the lung
invaded with 4T1/luc cells (Figure 7E, day 18, top left). H&E anal-
ysis indicated that nine out of the ten animals in the control group
were presented with lung metastases, compared with two out of
ten DnMAML1 animals. Similar to animals treated with GSI-34,
we harvested primary tumors and stained for hypoxia marker
Glut-1. We observed obvious hypoxic regions that were preva-
lent in both control and DnMAML1 tumors (Figure 7F). Further-
more, we did not detect marked differences in the g-secretase
activity of these tumors on day 18 (Figure S4E). Consistent
with our previously mentioned in vitro data, DnMAML1 tumors
also displayed decreased expression of Hes1 mRNA (Fig-
ure S4F). Together, these data demonstrate that Notch signaling
has a profound influence in driving cancer metastasis in hypoxic
tumors. g-Secretase inhibition by GSI-34 and the downregula-
tion of Notch signaling by DnMAML1 were able to reduce the
tendency for metastasis to the lung in a highly metastatic 4T1
breast cancer metastasis model. The inhibition of g-secretase
potently suppresses both migration and invasion of breast
cancer cells and therefore could be a potential therapeutic
candidate for the treatment and/or delay the onset of metastatic
breast cancer.
DISCUSSION
The present study reveals a mechanism of g-secretase regula-
tion and a role for Hif-1a that is independent of its function as
a transcriptional regulator during hypoxia. First, we discovered
a role for Hif-1a that is entirely distinct from both the canonical
and noncanonical Hif-1a pathways previously reported. The
essential and nontranscriptional role of Hif-1a in the modulation
of g-secretase is supported by the following observations: (1)
knockdown of Hif-1a abolishes the potentiation of g-secretase
activity under hypoxia and upregulation of Hif-1a level stimulates
g-secretase activity in normoxia (Figure 3), and (2) chemical and
genetic inhibition of the transcription function of Hif-1a do not
affect the stimulation of g-secretase activity (Figure 3; Figure S1).
Second, we demonstrated that g-secretase displays enzymatic
plasticity in response to hypoxia through a mechanism that(D) Sensitivity of 4T1 cell migration to GSI-34 in wound-healing assay.
(E) Matrigel invasion assay of 4T1 cells with 0.1, 1, and 10 mM GSI-34; statistical
(F) Matrigel invasion assay of MDA-MB 231 cells with 10 mMGSI-34. All data are p
tailed unpaired t test otherwise stated, where *p < 0.05, **p < 0.01, and ***p < 0.
Celinvolves a direct interaction with Hif-1a. The binding of Hif-1a
to the g-secretase complex is demonstrated by multiple lines
of evidence: (1) Hif-1a was cocaptured by activity-based affinity
probe (Figure 4), and (2) Hif-1a was coimmunoprecipitated with
PS1 with anti-PS1 (Figure 4). Hif-1a is comigrated and cocap-
tured with the more active, high-molecular-weight g-secretase
complex (Figure S2). Finally, the Hif-1a-containing g-secretase
complex directly contributes to the migratory and invasive
phenotype of breast cancer cells through the enhancement of
Notch cleavage in cells and in vivo (Figures 6 and 7). Inhibition
of g-secretase activity or downregulation of Notch signaling
reduced the invasion and metastasis of breast cancer cells. In
this regard, our studies have uncovered a pathway for modu-
lating Notch signaling and offer a potential drug target for hypox-
ia-driven metastatic breast cancer.
The enhancement of g-secretase activity under hypoxic
conditions relies on two critical factors: inactive g-secretase
complexes and Hif-1a. While the existence of the inactive g-sec-
retase complex has been established (Beher et al., 2003; Gu
et al., 2004; Lai et al., 2003; Placanica et al., 2009), the function
of these complexes has been elusive. Our biochemical and
cellular studies demonstrate that Hif-1a converts inactive com-
plexes into active complexes, suggesting that the inactive com-
plex serves as a zymogen for activation when enzyme activity is
required. g-Secretase seizes themajor hypoxia regulator, Hif-1a,
for its activation and to achieve temporal regulation. It will be of
interest to further investigate whether this particular mechanism
for regulation of g-secretase also holds true for other forms of
cellular stress and environmental cues.
How does Hif-1a upregulate g-secretase activity? Results
from studies using active-site-directed inhibitors offer a critical
understanding of the mechanism underlying the activation of
the inactive g-secretase complex. We suggest that the orienta-
tion and/or coordination of the two catalytic Asp residues within
the inactive complex is unsuitable for catalysis and that the bind-
ing of Hif-1a to the inactive complex leads to the repositioning of
the catalytic dyad to generate an active form of the enzyme (Fig-
ure 4G). However, further insight into the precise structural
changes in g-secretase that are induced by Hif-1a will no doubt
require high-resolution structures of g-secretase, which are
currently unavailable. It will be important to identify peptides or
small molecules that can block or disrupt the interaction of
Hif-1a and g-secretase to precisely investigate the role of
Hif-1a in modulating g-secretase/Notch signaling in cancer
and other human disorders.
In the canonical Hif-1a pathway, Hif-1a functions as a master
transcriptional regulator of the hypoxic response pathway and
has been widely investigated in various physiological and path-
ological conditions (Bu¨chler et al., 2003; Semenza, 2002). In
addition, Hif-1a has been shown to interact with other proteins,
such as pyruvate kinase M2 (Luo et al., 2011) and presenilin
(De Gasperi et al., 2010), to enhance its stability and promote
Hif-1a signaling. Presenilin can also regulate the Hif-1asignificance was analyzed using one-way ANOVA (***p < 0.001).
resented asmean ± SD (nR 3), and statistical significance is evaluated by two-
001.
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Figure 6. g-Secretase Inhibition by GSI-34 Decreased Metastatic Progression of 4T1/luc In Vivo
(A) GSI-34 treatment led to a reduction of tumor volume. GSI-34 at 80 mg/kg and 160 mg/kg reduced primary tumor volume by 27% and 40%, respectively, by
day 20 compared with the vehicle (average ± SEM, n = 8).
(legend continued on next page)
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pathways to enhance the expression of Hif-1a through the cleav-
ages of amyloid precursor protein (APP) to generate APP intra-
cellular domain (Kaufmann et al., 2013). Despite previous report
that Hif-1a can bind to NICD1 to promote Notch signaling, our
present study clearly demonstrates that Hif-1a binds to g-secre-
tase and directly modulates its enzymatic activity. This finding is
distinct from both canonical and previously reported noncanon-
ical roles of Hif-1a. We also determine that the Hif-1a protein is
indispensable for the upregulation of g-secretase activity under
hypoxia, a process that is independent of its transcriptional ac-
tivity. Moreover, we demonstrate that recombinant Hif-1a binds
to and activates the g-secretase complex. We identify Hif-1a as
the nonessential subunit of g-secretase that can shift andmodu-
late enzyme equilibrium from the inactive complex to the active
form.
g-Secretase inhibitors (GSIs) are on trial for the treatment for
a variety of neoplasms, and some clinical benefit has been
observed (Gounder and Schwartz, 2012; Krop et al., 2012;
Schott et al., 2013; Tolcher et al., 2012; Wei et al., 2010). Notch
signaling plays an important role in cancer metastasis (Sethi and
Kang, 2011), and GSI treatment reduced Notch-mediated bone
metastasis of breast cancer (Sethi et al., 2011). Our studies
further indicate that GSIs can potentially be used as anti-invasive
and antimetastatic agents and more specifically in combination
with chemotherapy and radiotherapy as effective adjuvants to
prevent or delay the onset of metastatic disease.
The impact of hypoxia-mediated responses is not limited to
cancer. Hypoxia may influence neurological disease pathology,
such as Alzheimer’s disease and other age-related disorders.
Hypoxia has been shown to increase b-amyloid production (Li
et al., 2009) and accelerates the deposition of amyloid plaques
in Alzheimer’s disease transgenic mouse models (Sun et al.,
2006). Oxygen availability also regulates Notch signaling to influ-
ence stem cell differentiation, developmental programming
(Simon and Keith, 2008), as well as the outcome of ischemic
stroke (Arumugam et al., 2006). Understanding the regulation
g-secretase under physiological and pathological conditions
will facilitate the development of selective therapies to combat
and control the molecular pathogenesis and progression of
both cancer and Alzheimer’s disease.
EXPERIMENTAL PROCEDURES
Compounds
JC-8, Compound 3, Compound E, GSI-34, and L-685,458 are all synthesized
in our laboratory (Chun et al., 2004; Placanica et al., 2009; Shelton et al., 2009a;
Yang et al., 2009) and dissolved in DMSO.(B) In vivo luciferase images of tumors. The representative luciferase signal emitte
lower part of the animal signifies primary tumor, upper thoracic shows signal em
(C) The effect of GIS-34 treatment on 4T1 lung metastasis. Luciferase signal det
animal by LivingImage software (average ± SEM, n = 8).
(D) H&E staining. Excised lung were stained analyzed using H&E stainingmethod t
and B) contain large metastatic lesions, while GSI-34-treated animals (C–F) exhib
with black arrows and yellow dotted lines.
(E) Ex vivo g-Secretase activity of primary tumor samples. Primary tumor samples
decreased level of g-secretase activity compared to tumors from DMSO-treated
(F) Immunohistochemical staining of Glut-1. Glut-1 marker was used to stain for
In all samples (A)–(F), there was a strong indication of tumor hypoxia (brown stai
CelExocell g-Secretase Activity Assay
Breast cancer cell lines were seeded in 96-well culture plates and incubated
either under normoxic or hypoxic setting for 24 hr. Exocell g-secretase activity
was assayed as described previously (Shelton et al., 2009a) using N1-Sb1
substrate (Chau et al., 2012). See the Supplemental Experimental Procedures
for more details.
Activity-Based Photoaffinity Labeling and Capture
Activity-based photoaffinity labeling was performed with breast cancer cell
lines in 12-well tissue culture dish with 10 nM of JC-8 (Li et al., 2000; Shelton
et al., 2009b). Capture of the active g-secretase complex was first performed
under nondenaturing conditions using Compound 3 (Placanica et al., 2009).
See the Supplemental Experimental Procedures for more details.
Reconstitution Studies
Breast cancer cells (MCF-7 and 4T1) were cosolubilized withMBP orMBP-Hif-
1a in PIPES buffer containing 1%CHAPSO for 1 hr at 4C. Solubilized fractions
were used for assaying g-secretase activity and activity-based photolabeling.
See the Supplemental Experimental Procedures for more details.
Mouse Mammary Metastasis Model and Bioluminescence Imaging
Animal studies were performed according to protocols approved by the Me-
morial Sloan Kettering Cancer Center animal facility. See the Supplemental
Experimental Procedures for more details.
Immunohistochemistry
Primary tumor and lung samples were immediately fixed upon dissection in
4% paraformaldehyde (v/v) in PBS overnight at 4C. See the Supplemental
Experimental Procedures for more details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.07.028.
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Figure 7. Effect of Downregulation of Notch Signaling by DnMAML on Tumor Growth and Metastasis In Vivo
(A) DnMAML1 cells express reduced levels of Notch downstream gene Hes1 compared to control cells as determined by quantitative RT-PCR.
(B) Effect on tumor volume. Animals bearing control 4T1 cells and DnMAML1 4T1 cells exhibited similar tumor latency and growth rate throughout the progression
of the course of the experiment (average ± SEM, n = 10).
(C) Metastatic progression of DnMAML1 and control animals in vivo. The same procedure in (B) was used for the analysis of lung metastasis luciferase signal
detected expressed as total flux (p/s) quantitated by LivingImage software (average ± SEM, control [n = 9], DnMAML1 [n = 10]).
(legend continued on next page)
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